BIIB vs CMPX Valuation Comparison 2026 — Intrinsic Value Analysis

Quick Summary — BIIB scores higher on quality with 8.4/10 vs CMPX's 5.3/10. BIIB trades at $188.83 while CMPX trades at $2.08. Both analyzed daily using SEC EDGAR data across 13 institutional models.

BIIB

Biological Products, (No Diagnostic Substances)

Biogen Inc.

Quality

8.4

out of 10

Value Trap

23

SAFE

Price

$188.83

Last close

Models

13/13

Active

VS

CMPX

Biological Products, (No Diagnostic Substances)

Compass Therapeutics, Inc.

Quality

5.3

out of 10

Value Trap

30

LOW

Price

$2.08

Last close

Models

9/13

Active

BIIB

Quality Score 8.4/10 — top tier

Limited to 2/13 visible models

CMPX

2 models active

Limited to 2/13 visible models

BIIB vs CMPX — Fair Value Comparison

BIIB

CMPX

Market Price Model 1 Model 2

Model-by-Model Comparison

Model	Type	BIIB Fair Value	BIIB Upside	CMPX Fair Value	CMPX Upside
Bayesian DCF	Intrinsic	$136.51	-27.7%	$0.65	-69.0%
Earnings Power Value	Intrinsic	$103.55	-45.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$215.59	+14.2%	$0.18	-90.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

BIIB vs CMPX — Which Stock Is More Undervalued in 2026?

BIIB scores higher with a 8.4/10 quality rating vs CMPX's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do BIIB and CMPX Valuations Compare?

At $188.83, BIIB trades +27.7% above its Bayesian DCF fair value of $136.51, while CMPX at $2.08 trades +69.0% above its estimate of $0.65. CMPX shows a wider gap between price and intrinsic value.

Quality of Company: BIIB vs CMPX

BIIB earns a Quality of Company score of 8.4/10 compared to CMPX's 5.3/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: BIIB vs CMPX

BIIB carries a SAFE value trap risk (23/100) while CMPX shows LOW risk (30/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.

Both in Biological Products, (No Diagnostic Substances)

Both BIIB and CMPX operate in Biological Products, (No Diagnostic Substances), which has 6 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare BIIB vs CMPX differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

BIIB

View Full Biogen Inc. Analysis →

CMPX

View Full Compass Therapeutics, Inc. Analysis →